evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1 questions · 1 findings · 1 reviews · Lung Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Next‐generation ALK inhibitor vs crizotinib

Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).

1 finding from 1 review